Vanessa Bonazzi

2.3k total citations
27 papers, 784 citations indexed

About

Vanessa Bonazzi is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Vanessa Bonazzi has authored 27 papers receiving a total of 784 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Molecular Biology, 11 papers in Cancer Research and 9 papers in Oncology. Recurrent topics in Vanessa Bonazzi's work include Fibroblast Growth Factor Research (6 papers), MicroRNA in disease regulation (5 papers) and Cancer Cells and Metastasis (4 papers). Vanessa Bonazzi is often cited by papers focused on Fibroblast Growth Factor Research (6 papers), MicroRNA in disease regulation (5 papers) and Cancer Cells and Metastasis (4 papers). Vanessa Bonazzi collaborates with scholars based in Australia, France and Italy. Vanessa Bonazzi's co-authors include Nicholas K. Hayward, Mitchell Stark, Glen M. Boyle, Lauren G. Aoude, Darryl Irwin, Christopher Schmidt, Pamela M. Pollock, Richard A. Sturm, Ken Dutton‐Regester and Elke Hacker and has published in prestigious journals such as PLoS ONE, Scientific Reports and Biochemical and Biophysical Research Communications.

In The Last Decade

Vanessa Bonazzi

25 papers receiving 776 citations

Peers

Countries citing papers authored by Vanessa Bonazzi

Since Specialization

Citations

This map shows the geographic impact of Vanessa Bonazzi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vanessa Bonazzi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vanessa Bonazzi more than expected).

Fields of papers citing papers by Vanessa Bonazzi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vanessa Bonazzi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vanessa Bonazzi. The network helps show where Vanessa Bonazzi may publish in the future.

Co-authorship network of co-authors of Vanessa Bonazzi

This figure shows the co-authorship network connecting the top 25 collaborators of Vanessa Bonazzi. A scholar is included among the top collaborators of Vanessa Bonazzi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vanessa Bonazzi. Vanessa Bonazzi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Spatial intra-tumour heterogeneity and treatment-induced genomic evolution in oesophageal adenocarcinoma: implications for prognosis and therapy 2024 ·Genome Medicine ·Sandra Brosda, Lauren G. Aoude, Vanessa Bonazzi, Kalpana Patel, James M. Lonie, (unknown), Felicity Newell, Lambros T. Koufariotis, Venkateswar Addala, Marjan Mojtabavi Naeini, (unknown), (unknown), (unknown), Andrew P. Barbour, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	4
2	Circulating Tumor DNA 2023 ·Journal of Molecular Diagnostics ·Lauren G. Aoude, Sandra Brosda, Jessica Ng, James M. Lonie, (unknown), Kalpana Patel, Lambros T. Koufariotis, Scott Wood, Victoria Atkinson, B. Mark Smithers, John V. Pearson, Nicola Waddell, Andrew P. Barbour, Vanessa Bonazzi	9
3	Endometrial cancer PDX-derived organoids (PDXOs) and PDXs with FGFR2c isoform expression are sensitive to FGFR inhibition 2023 ·npj Precision Oncology ·(unknown), Vanessa Bonazzi, Deborah S. Smith, Cristian P. Moiola, Rohan Lourie, Rebecca F. Rogers, Eva Colás, Antonio Gil‐Moreno, Sophia Frentzas, Naven Chetty, Lewis Perrin, Pamela M. Pollock	11
4	The oesophageal adenocarcinoma tumour immune microenvironment dictates outcomes with different modalities of neoadjuvant therapy – results from the AGITG DOCTOR trial and the cancer evolution biobank 2023 ·Frontiers in Immunology ·James M. Lonie, Sandra Brosda, Vanessa Bonazzi, Lauren G. Aoude, Kalpana Patel, Ian Brown, (unknown), Guy Lampe, Venkateswar Addala, Lambros T. Koufariotis, Scott Wood, Nicola Waddell, Riccardo Dolcetti, Andrew P. Barbour	6
5	C‐reactive protein is a prognostic biomarker in pancreatic ductal adenocarcinoma patients 2023 ·Asia-Pacific Journal of Clinical Oncology ·Vanessa Bonazzi, Lauren G. Aoude, Sandra Brosda, (unknown), James M. Lonie, Kelly A. Loffler, Michael G. Gartside, Kalpana Patel, Pamela Mukhopadhyay, Colm Keane, Val Gebski, James G. Kench, David Goldstein, Nicola Waddell, Andrew P. Barbour, (unknown)	5
6	ctDNA as a biomarker of progression in oesophageal adenocarcinoma 2022 ·ESMO Open ·Vanessa Bonazzi, Lauren G. Aoude, Sandra Brosda, James M. Lonie, Kalpana Patel, (unknown), Lambros T. Koufariotis, Scott Wood, B. Mark Smithers, Nicola Waddell, Andrew P. Barbour	15
7	Characterizing the Heterogeneity of Small Extracellular Vesicle Populations in Multiple Cancer Types via an Ultrasensitive Chip 2021 ·ACS Sensors ·Jing Wang, Alain Wuethrich, Richard J. Lobb, Fiach Antaw, Abu Ali Ibn Sina, Rebecca E. Lane, (unknown), (unknown), (unknown), Vanessa Bonazzi, Lauren G. Aoude, Sarah Everitt, Belinda Yeo, Andrew P. Barbour, Andreas Möller, Matt Trau	33
8	Pathogenic germline variants are associated with poor survival in stage III/IV melanoma patients 2020 ·Scientific Reports ·Lauren G. Aoude, Vanessa Bonazzi, Sandra Brosda, Kalpana Patel, Lambros T. Koufariotis, Harald Oey, Kátia Nones, Scott Wood, John V. Pearson, James M. Lonie, (unknown), Victoria Atkinson, B. Mark Smithers, Nicola Waddell, Andrew P. Barbour	12
9	PI3K Inhibitors Synergize with FGFR Inhibitors to Enhance Antitumor Responses in FGFR2mutant Endometrial Cancers 2017 ·Molecular Cancer Therapeutics ·Leisl Packer, (unknown), Vanessa Bonazzi, Robert J. Ju, (unknown), Margaret C. Cummings, Sally‐Anne Stephenson, Pamela M. Pollock	32
10	Combination of BGJ398 with either a pan-PI3K inhibitor or a specific PIK3CA inhibitor shows synergy in FGFR2 mutant endometrial cancer cell lines 2016 ·European Journal of Cancer ·Leisl Packer, (unknown), Vanessa Bonazzi, (unknown), Robert J. Ju, Sally‐Anne Stephenson, Pamela M. Pollock	0
11	miR-514a regulates the tumour suppressor NF1 and modulates BRAFi sensitivity in melanoma 2015 ·QUT ePrints (Queensland University of Technology) ·Mitchell Stark, Vanessa Bonazzi, Glen M. Boyle, Jane M. Palmer, Judith Symmons, Catherine Lanagan, Christopher Schmidt, Adrian C. Herington, Robert Ballotti, Pamela M. Pollock, Nicholas K. Hayward	1
12	Abstract B114: Combination of BGJ398 with either a pan-PI3K inhibitor or a specific PIK3CA inhibitor shows synergy in FGFR2 mutant endometrial cancer cell lines 2015 ·Molecular Cancer Therapeutics ·Pamela M. Pollock, (unknown), Vanessa Bonazzi, (unknown), Sally‐Anne Stephenson, Leisl Packer	1
13	Melanoma cell invasiveness is regulated by miR‐211 suppression of the BRN2 transcription factor 2011 ·Pigment Cell & Melanoma Research ·Glen M. Boyle, Susan L. Woods, Vanessa Bonazzi, Mitchell Stark, Elke Hacker, Lauren G. Aoude, Ken Dutton‐Regester, Anthony L. Cook, Richard A. Sturm, Nicholas K. Hayward	142
14	MicroRNA regulation of melanoma progression 2011 ·Melanoma Research ·Vanessa Bonazzi, Mitchell Stark, Nicholas K. Hayward	56
15	Cross-Platform Array Screening Identifies COL1A2, THBS1, TNFRSF10D and UCHL1 as Genes Frequently Silenced by Methylation in Melanoma 2011 ·PLoS ONE ·Vanessa Bonazzi, Derek J. Nancarrow, Mitchell Stark, Ralf Moser, Glen M. Boyle, Lauren G. Aoude, Christopher Schmidt, Nicholas K. Hayward	72
16	H‐Cadherin expression reduces invasion of malignant melanoma 2009 ·Pigment Cell & Melanoma Research ·Silke Kuphal, A. Martyn, Julie Pedley, Lisa M. Crowther, Vanessa Bonazzi, Peter G. Parsons, Anja‐Katrin Bosserhoff, Nicholas K. Hayward, Glen M. Boyle	50
17	Identification of candidate tumor suppressor genes inactivated by promoter methylation in melanoma 2008 ·Genes Chromosomes and Cancer ·Vanessa Bonazzi, Darryl Irwin, Nicholas K. Hayward	65
18	Complementation analyses suggest species-specific functions of the SNF5 homology domain 2005 ·Biochemical and Biophysical Research Communications ·Vanessa Bonazzi, Souhila Medjkane, Frédérique Quignon, Olivier Delattre	1
19	Vascular endothelial growth factor (VEGF) and other common tissue prognostic indicators in breast cancer: A case-control study 2004 ·The International Journal of Biological Markers ·Andrea Nicolini, Daniela Campani, Paolo Miccoli, C Spinelli, Angelo Carpi, Michele Menicagli, Paola Ferrari, (unknown), Gabriele Rossi, Milena Fini, Gianluca Giavaresi, Vanessa Bonazzi, Roberto Giardino	13
20	Oral low-dose cyclophosphamide in metastatic hormone refractory prostate cancer (MHRPC) 2004 ·Biomedicine & Pharmacotherapy ·Andrea Nicolini, (unknown), Paola Ferrari, L Anselmi, G. Tartarelli, Vanessa Bonazzi, Angelo Carpi, Roberto Giardino	58

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact